Five UC San Francisco faculty members are among the 70 new members elected to the National Academy of Medicine (NAM), formerly known as the Institute of Medicine (IOM).

Each year, UCSF participates in the massive technology gathering by Salesforce, highlighting the latest innovations in health care and research.

A coalition of leukemia researchers led by scientists from UC San Francisco has discovered surprising genetic diversity in juvenile myelomonocytic leukemia (JMML), a rare but aggressive childhood blood cancer.

Online advertising based on Google search terms is a potentially effective way to deliver targeted cancer prevention education, according to a study led by Eleni Linos, MD, DrPH, an assistant professor of dermatology at UC San Francisco.

The National Institutes of Health (NIH) has awarded seven grants to UC San Francisco scientists to pursue innovative approaches to major contemporary challenges in biomedical research.

Breast cancer is the most common kind of cancer among American women, except for skin cancer, and the second leading cause of cancer death in women, exceeded only by lung cancer. But emerging knowledge offers reason for optimism. Here are five things women should know about breast cancer, according to Dr. Laura Esserman.

Three UCSF researchers were awarded a total of $560,000 to support projects in breast cancer research. These grants are among those made to 124 researchers in 25 states and 15 countries, with about half of the grants targeted to early-career investigators.

UC San Francisco researchers have engineered a molecular “on switch” that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer.

Metastases cause the vast majority of cancer deaths, but their tiny seeds are so difficult to track that few researchers have managed to study them. Now, scientists from UC San Francisco describe capturing and studying individual metastatic cells from human breast cancer tumors implanted into mice as the cells escaped into the blood stream and began to form tumors elsewhere in the body.

The next frontier in developing therapies for cancer and other diseases could come through studying organ development or tumor growth in living humans. Problem is, there’s no ethical way of doing that using current technology. Zev Gartner, PhD, has focused on the next best thing: His lab is building fully functioning 3-D human tissue, cell by cell.